川崎病发病机制及诊疗进展
Pathogenesis of Kawasaki Disease and Progress in Diagnosis and Treatment
DOI: 10.12677/acm.2026.1641226, PDF,   
作者: 庞艳棋, 龚 放*:重庆医科大学附属永川医院,重庆
关键词: 川崎病发病机制诊断标准治疗Kawasaki Disease (KD) Pathogenesis Diagnostic Criteria Treatment
摘要: 川崎病(Kawasaki disease, KD)又名皮肤黏膜淋巴结综合征,是一种病因不明的累及全身中小血管的系统性血管炎。以发热、皮疹、手足硬肿、黏膜改变等为主要表现,根据临床表现分为完全性川崎病(Complete Kawasaki disease, CKD)及不完全型川崎病(Incomplete Kawasaki disease, IKD)。该病好发于5岁以下儿童,尤其是6个月至2岁的幼儿,男女比例为1.8:1,是儿童时期最常见的获得性心脏病病因,最危险的并发症是冠状动脉损伤(Coronary artery lesion, CAL),严重时可导致冠状动脉瘤(Coronary artery aneurysm, CAA)、心肌梗死,甚至猝死。因此,早发现、早诊断、早治疗对于KD尤为重要。本文针对川崎病最新发病机制研究、特殊类型的诊断及治疗方案进行总结,以期为KD临床诊疗提供依据。
Abstract: Kawasaki disease (KD), also known as mucocutaneous lymph node syndrome, which is a systemic vasculitis of unknown etiology affecting small and medium-sized blood vessels throughout the body. Its primary manifestations include fever, rash, hard swelling of the hands and feet, and mucosal changes. Based on clinical presentation, it is classified into complete Kawasaki disease (CKD) and incomplete Kawasaki disease (IKD). This disease predominantly affects children under 5 years old, particularly those aged 6 months to 2 years, with a male-to-female ratio of 1.8:1. It is the most common cause of acquired heart disease in childhood. The most dangerous complication is coronary artery lesion (CAL), which in severe cases can lead to coronary artery aneurysm (CAA), myocardial infarction, or even sudden death. Therefore, early detection, diagnosis, and treatment are crucial for KD. This article summarizes the latest research on the pathogenesis of Kawasaki disease, the diagnosis of special subtypes, and treatment strategies, aiming to provide a basis for the clinical diagnosis and treatment of KD.
文章引用:庞艳棋, 龚放. 川崎病发病机制及诊疗进展[J]. 临床医学进展, 2026, 16(4): 68-75. https://doi.org/10.12677/acm.2026.1641226

参考文献

[1] Galeotti, C., Kaveri, V.S., Cimaz, R., et al. (2016) Predisposing Factors, Pathogenesis and Therapeutic Intervention of Kawasaki Disease. Drug Discovery Today, 21, 1850-1857. [Google Scholar] [CrossRef] [PubMed]
[2] Wu, J., Yu, M., Huang, L., Qian, Y., Kong, M., Kang, Z., et al. (2020) Association of Mnsod Gene Polymorphism with Susceptibility to Kawasaki Disease in Chinese Children. Cardiology in the Young, 31, 179-185. [Google Scholar] [CrossRef] [PubMed]
[3] DeHaan, L.L., Copeland, C.D., Burney, J.A., Nakamura, Y., Yashiro, M., Shimizu, C., et al. (2024) Age-Dependent Variations in Kawasaki Disease Incidence in Japan. JAMA Network Open, 7, e2355001. [Google Scholar] [CrossRef] [PubMed]
[4] Namba, T., Takeuchi, A., Matsumoto, N., Tsuge, M., Yashiro, M., Tsukahara, H., et al. (2023) Evaluation of the Association of Birth Order and Group Childcare Attendance with Kawasaki Disease Using Data from a Nationwide Longitudinal Survey. Frontiers in Pediatrics, 11, Article 1127053. [Google Scholar] [CrossRef] [PubMed]
[5] Hara, T., Furuno, K., Yamamura, K., Kishimoto, J., Mizuno, Y., Murata, K., et al. (2021) Assessment of Pediatric Admissions for Kawasaki Disease or Infectious Disease during the COVID-19 State of Emergency in Japan. JAMA Network Open, 4, e214475. [Google Scholar] [CrossRef] [PubMed]
[6] 顾昕雨, 龚方戚. 川崎病病因学研究进展[J]. 中国实用儿科杂志, 2025, 40(5): 425-432.
[7] Ding, Y., Ren, Y., Feng, X., Xu, Q., Sun, L., Zhang, J., et al. (2013) Correlation between Brachial Artery Flow-Mediated Dilation and Endothelial Microparticle Levels for Identifying Endothelial Dysfunction in Children with Kawasaki Disease. Pediatric Research, 75, 453-458. [Google Scholar] [CrossRef] [PubMed]
[8] Burns, J.C. (2024) The Etiologies of Kawasaki Disease. Journal of Clinical Investigation, 134, e176938. [Google Scholar] [CrossRef] [PubMed]
[9] Chang, L., Yang, H., Lin, T. and Yang, K.D. (2021) Perspective of Immunopathogenesis and Immunotherapies for Kawasaki Disease. Frontiers in Pediatrics, 9, Article 697632. [Google Scholar] [CrossRef] [PubMed]
[10] Roe, K. (2020) A Viral Infection Explanation for Kawasaki Disease in General and for COVID-19 Virus-Related Kawasaki Disease Symptoms. Inflammopharmacology, 28, 1219-1222. [Google Scholar] [CrossRef] [PubMed]
[11] Freeman, A.F. and Shulman, S.T. (2006) Kawasaki Disease: Summary of the American Heart Association Guidelines. American Family Physician, 74, 1141-1148.
[12] 樊志丹, 俞海国, 胡坚, 等. 中国儿童血管炎诊断与治疗系列专家共识之四——川崎病[J]. 中国实用儿科杂志, 2023, 38(7): 481-488.
[13] Lopez, L., Frommelt, P.C., Colan, S.D., Trachtenberg, F.L., Gongwer, R., Stylianou, M., et al. (2021) Pediatric Heart Network Echocardiographic Z Scores: Comparison with Other Published Models. Journal of the American Society of Echocardiography, 34, 185-192. [Google Scholar] [CrossRef] [PubMed]
[14] 陆召安, 王丽杰, 刘辉, 等. 超声心动图对川崎病患者冠状动脉病变的诊断价值及其血流动力学变化[J]. 医学影像学杂志, 2025, 35(10): 62-65.
[15] 王春笛, 赵丽, 秦雯, 等. 川崎病患儿并发冠状动脉损伤的危险因素及预测模型的构建与评价[J]. 现代生物医学进展, 2023, 23(19): 3636-3641.
[16] Mu, Z.L., Jiao, F.Y. and Xie, K.S. (2021) Interpretation of the JCS/JSCS 2020 Guideline on Diagnosis and Management of Cardiovascular Sequelae in Kawasaki Disease. Chinese Journal of Contemporary Pediatrics, 23, 213-220.
[17] 李晓敏, 杨轶男, 侯贺阳, 等. 川崎病129例临床特征及并发冠状动脉损伤影响因素分析[J]. 兰州大学学报(医学版), 2023, 49(12): 69-75.
[18] Miyata, K., Bainto, E.V., Sun, X., Jain, S., Dummer, K.B., Burns, J.C., et al. (2023) Infliximab for Intensification of Primary Therapy for Patients with Kawasaki Disease and Coronary Artery Aneurysms at Diagnosis. Archives of Disease in Childhood, 108, 833-838. [Google Scholar] [CrossRef] [PubMed]
[19] Burns, J.C., Roberts, S.C., Tremoulet, A.H., He, F., Printz, B.F., Ashouri, N., et al. (2021) Infliximab versus Second Intravenous Immunoglobulin for Treatment of Resistant Kawasaki Disease in the USA (KIDCARE): A Randomised, Multicentre Comparative Effectiveness Trial. The Lancet Child & Adolescent Health, 5, 852-861. [Google Scholar] [CrossRef] [PubMed]
[20] 苗立坤, 陈素芬, 蔡继锐, 等. 川崎病合并冠状动脉瘤的研究进展[J]. 心血管病学进展, 2025, 46(6): 507-510.
[21] 钱翠平, 郑丽云, 祁晓慧, 等. 英夫利昔单抗在川崎病治疗中的研究进展[J]. 中国分子心脏病学杂志, 2024, 24(5): 6412-6415.
[22] Hoang, L.T., Shimizu, C., Ling, L., Naim, A.N.M., Khor, C.C., Tremoulet, A.H., et al. (2014) Global Gene Expression Profiling Identifies New Therapeutic Targets in Acute Kawasaki Disease. Genome Medicine, 6, Article No. 541. [Google Scholar] [CrossRef] [PubMed]
[23] Portman, M.A., Dahdah, N.S., Slee, A., Olson, A.K., Choueiter, N.F., Soriano, B.D., et al. (2019) Etanercept with IVIg for Acute Kawasaki Disease: A Randomized Controlled Trial. Pediatrics, 143, e20183675. [Google Scholar] [CrossRef] [PubMed]
[24] Tremoulet, A.H., Pancoast, P., Franco, A., Bujold, M., Shimizu, C., Onouchi, Y., et al. (2012) Calcineurin Inhibitor Treatment of Intravenous Immunoglobulin-Resistant Kawasaki Disease. The Journal of Pediatrics, 161, 506-512.e1. [Google Scholar] [CrossRef] [PubMed]
[25] Kitamura, S. and Tsuda, E. (2019) Significance of Coronary Revascularization for Coronary-Artery Obstructive Lesions Due to Kawasaki Disease. Children, 6, Article 16. [Google Scholar] [CrossRef] [PubMed]
[26] McCrindle, B.W., Rowley, A.H., Newburger, J.W., et al. (2017) Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement from the American Heart Association. Circulation, 135, e927-e999.
[27] Kanegaye, J.T., Wilder, M.S., Molkara, D., Frazer, J.R., Pancheri, J., Tremoulet, A.H., et al. (2009) Recognition of a Kawasaki Disease Shock Syndrome. Pediatrics, 123, e783-e789. [Google Scholar] [CrossRef] [PubMed]
[28] Lao, F., Robinson, C.H., Borovsky, D., Ewusie, J., Beattie, K. and Batthish, M. (2025) Long-Term Cardiovascular Outcomes and Mortality Following Kawasaki Disease: A Systematic Review and Meta-Analysis. Paediatrics & Child Health, 30, 406-413. [Google Scholar] [CrossRef
[29] Yokouchi, Y., Asakawa, N., Sato, W., Asakura, K., Hayashi, K., Nakamura, Y., et al. (2026) Association of Coronary Vasculitis Sequelae with Atherosclerosis in Adults with a History of Kawasaki Disease: Autopsy Pathological Findings. Arteriosclerosis, Thrombosis, and Vascular Biology, 46, e323903. [Google Scholar] [CrossRef
[30] 吴佳慧, 成芳芳, 孔小行, 等. 再发川崎病的临床特点及相关危险因素分析[J]. 临床儿科杂志, 2020, 38(7): 485-489.